Skip to content

Johnson & Johnson JNJ Cash & Equivalents

Cash & Equivalents at other companies

Abbott logo
AbbottABT
$6.8B+4.1%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$9.57B-12.0%
Tenet Healthcare logo
Tenet HealthcareTHC
$2.97B-1.1%
Pfizer logo
PfizerPFE
$1.76B+18.8%
Procter & Gamble logo
Procter & GamblePG
$12.31B+35.0%
Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%

Other financials

Income statement

See full
Revenue$25.3B+6.6%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.27-0.9%

Balance sheet

See full
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$611.07B+62.5%
Enterprise value$644.37B+50.5%
P/S6.2×+2.1×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's cash & equivalents?
Johnson & Johnson (JNJ) reported cash & equivalents of $21.69B in Q1 2026.
How has Johnson & Johnson's cash & equivalents changed year-over-year?
Johnson & Johnson's cash & equivalents decreased by 43.6% year-over-year, from $38.47B to $21.69B.
What is the long-term trend for Johnson & Johnson's cash & equivalents?
Over 5 years (2020 to 2025), Johnson & Johnson's cash & equivalents has grown at a 7.1% compound annual growth rate (CAGR), from $13.99B to $19.71B.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.